L'intérêt à découvert pour Evoke Pharma donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Evoke Pharma. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Evoke Pharma (NASDAQ:EVOK) Stock, Rapport sur les intérêts à découvert

Evoke Pharma

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma Inc

EvokAI Creative Labs Inc

EVOKAI CREATIVE LABS INC by EVOKAI CREATIVE LABS INC.

888 HOLDINGS PLC ORD by 888 Holdings plc.

Evoke PLC

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
The Dow traded up 0.18% to 44,319.31 while the NASDAQ gained 0.62% to 20,545.29. The S&amp;P 500 also rose, gaining, 0.31% to 6,245.11.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 1.1% on Wednesday.
In trading on Wednesday, consumer staples stocks dipped by 1%.
Top Headline
U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, recording the biggest gain since January, the EIA said.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Calidi Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) shares shot up 353% to $1.48. The stock's surge comes on the heels of a development in the healthcare sector. Calidi Biotherapeutics has been making headlines for its innovative approaches to cancer treatment.</li>
<li>Shares of SU Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) got a boost, surging 155% to $1.1609 after the company was awarded an HK$88.5 million hospital contract.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 171% to $7.20 after the company announced it received a notice of allowance for the U.S. patent application covering GIMOTI in patients with moderate to severe symptoms of Gastroparesis.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Bitmine Immersion Technologies, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NASDAQ">BMNR</a>) shares dropped 47% to $59.22. BitMine Immersion Technologies filed for mixed shelf.</li>
<li>Shares of RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) were down 42% to $7.39 after the company cut its 2025 revenue guidance from $160M–$175M to $120M–$130M.</li>
<li>Vertical Aerospace Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NASDAQ">EVTL</a>) was down, falling 31% to $4.77 as the company announced the pricing of $60 million underwritten public offering at a price of $5/share.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $68.74 while gold traded down 0.1% at $3,315.70.
Silver traded down 0.4% to $36.610 on Wednesday, while copper fell 3.8% to $5.4715.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.71%, while Spain's IBEX 35 Index rose 1.07%. London's FTSE 100 gained 0.13%, Germany's DAX 40 gained 1.32% and France's CAC 40 gained 1.40% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei gaining 0.33%, Hong Kong's Hang Seng falling 1.06%, China's Shanghai Composite declining 0.13% and India's BSE Sensex falling 0.21%.
Economics
<ul class="wp-block-list">
<li>U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May in-line with the preliminary estimate and compared to a 0.1% increase in the previous month.</li>
<li>U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, recording the biggest gain since January, the EIA said.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46320283/this-microsoft-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday">This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday</a></li>
</ul>
Photo via Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BMNR

CLDI

EVOK

EVTL

RXST

SUGP

Crude Oil Moves Higher; RxSight Shares Plunge

<h3>Gainers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock increased by 225.2% to $1.09 during Wednesday's regular session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 169.54% to $7.17. The market value of their outstanding shares is at $3.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares increased by 72.81% to $3.15. The market value of their outstanding shares is at $34.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 43.07% to $0.08. The company's market cap stands at $21.2 million. </li>
<li>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) stock moved upwards by 32.72% to $86.46. The company's market cap stands at $4.1 billion. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares moved upwards by 29.08% to $8.81. The company's market cap stands at $38.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares fell 37.7% to $7.97 during Wednesday's regular session. The company's market cap stands at $519.7 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares declined by 27.43% to $6.09. The company's market cap stands at $229.0 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock decreased by 17.44% to $0.64. The market value of their outstanding shares is at $3.6 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares declined by 17.12% to $114.24. The market value of their outstanding shares is at $767.1 million. </li>
<li>Pelthos Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#AMEX">PTHS</a>) stock declined by 14.09% to $17.08. The company's market cap stands at $13.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 12.34% to $0.69. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMGL

BSGM

KZIA

NCNA

NUTX

PTHS

RYTM

WINT

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

Shares of Evoke Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) are trading sharply higher Wednesday morning after the specialty pharmaceutical company <a href="https://www.benzinga.com/pressreleases/25/07/g46316671/evoke-pharma-receives-notice-of-allowance-for-u-s-patent-application-for-gimoti-extending-orange-b">announced</a> it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI.
What To Know: The nasal spray is a treatment for adults with moderate to severe symptoms of diabetic gastroparesis. The new patent, which is expected to expire in December 2036, will extend the market exclusivity for GIMOTI&#xAE;, a non-oral formulation of metoclopramide. 
Evoke Pharma plans to list the patent in the FDA&#8217;s Orange Book, a key move in protecting the drug from generic competition. This news sent the company&#8217;s stock price into overdrive, with shares trading significantly higher in Wednesday&#8217;s session.
&#8220;This new patent allowance adds meaningful value to the GIMOTI&#xAE; franchise by reinforcing protection around how and in whom the therapy is used,&#8221; said Matt D&#8217;Onofrio, CEO of Evoke Pharma.
The company stated this patent strengthens GIMOTI&#8217;s position as a critical treatment option for a patient population that often struggles with the effectiveness of traditional pills.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EVOK shares are trading higher by 171.6% to $7.29 Wednesday morning. The stock has a 52-week high of $12.32 and a 52-week low of $1.94.
Read Also: <a href="https://www.benzinga.com/pressreleases/25/07/g46316671/evoke-pharma-receives-notice-of-allowance-for-u-s-patent-application-for-gimoti-extending-orange-b">Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036</a>
<h2 class="wp-block-heading">How To Buy EVOK Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Evoke Pharma&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.46% to 44,442.42 while the NASDAQ gained 0.95% to 20,611.65. The S&amp;P 500 also rose, gaining, 0.60% to 6,262.70.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 1.6% on Wednesday.
In trading on Wednesday, energy stocks dipped by 0.6%.
Top Headline
U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May in-line with the preliminary estimate and compared to a 0.1% increase in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Calidi Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) shares shot up 242% to $1.1463. The stock's surge comes on the heels of a development in the healthcare sector. Calidi Biotherapeutics has been making headlines for its innovative approaches to cancer treatment.</li>
<li>Shares of SU Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) got a boost, surging 203% to $1.36 after the company was awarded an HK$88.5 million hospital contract.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 150% to $6.65 after the company announced it received a notice of allowance for the U.S. patent application covering GIMOTI in patients with moderate to severe symptoms of Gastroparesis.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Park Ha Biological Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) shares dropped 53% to $1.4001.</li>
<li>Shares of RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) were down 40% to $7.68 after the company cut its 2025 revenue guidance from $160M–$175M to $120M–$130M.</li>
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) was down, falling 33% to $36.50.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $67.82 while gold traded down 0.1% at $3,315.70.
Silver traded down 0.5% to $36.575 on Wednesday, while copper fell 3% to $5.5145.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.8%, while Spain's IBEX 35 Index rose 1%. London's FTSE 100 gained 0.1%, Germany's DAX 40 gained 1.4% and France's CAC 40 gained 1.4% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei gaining 0.33%, Hong Kong's Hang Seng falling 1.06%, China's Shanghai Composite declining 0.13% and India's BSE Sensex falling 0.21%.
Economics
U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May in-line with the preliminary estimate and compared to a 0.1% increase in the previous month.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46320283/this-microsoft-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday">This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May

WIIM

Evoke Pharma shares are trading higher after the company announced it received a notice of allowance for the U.S. patent application covering GIMOTI in patients with moderate to severe symptoms of Gastroparesis.

Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE; (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI&#xAE; in patients with moderate to severe symptoms of gastroparesis.
The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke's intellectual property estate around intranasal metoclopramide. Upon issuance, the patent will be expected to expire in December 2036 and the company intends to list the patent in the FDA's Orange Book, extending market exclusivity for GIMOTI&#xAE; beyond other existing patents.
Evoke Pharma has filed another U.S. continuation application to pursue additional claims directed to treatments for this patient population.
As part of its commitment to the gastroparesis community, Evoke is proud to support Gastroparesis Awareness Month this August, and recognizes the importance of improving treatment options and disease awareness for patients facing this chronic and often debilitating condition.
GIMOTI is the only FDA-approved, non-oral, self-administered formulation of metoclopramide and is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Non-oral delivery is an important treatment option as gastroparesis causes oral medications to be unpredictably absorbed and is vulnerable to one of the key symptoms of the disease, vomiting.

Evoke Pharma Receives Notice Of Allowance From USPTO For U.S. Patent Application Covering Use Of GIMOTI In Patients With Moderate To Severe Symptoms Of Gastroparesis

<h3>Gainers</h3>
<ul>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) stock rose 85.8% to $8.71 during Friday's regular session. The company's market cap stands at $606.9 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares rose 54.86% to $0.79. The market value of their outstanding shares is at $5.9 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares rose 48.68% to $2.26. The market value of their outstanding shares is at $3.3 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock moved upwards by 39.16% to $1.86. The company's market cap stands at $48.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 38.76% to $7.96. The market value of their outstanding shares is at $217.4 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 29.87% to $0.05. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares fell 29.0% to $21.74 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock fell 24.62% to $2.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 15.17% to $1.29. The market value of their outstanding shares is at $132.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 15.1% to $0.51. The company's market cap stands at $12.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 13.4% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 13.39% to $0.53. The market value of their outstanding shares is at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAY

BJDX

CYCC

NUWE

PHAT

SCNI

SXTC

VERA

12 Health Care Stocks Moving In Friday's Intraday Session

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.33) by 54.55 percent. This is a 75.6 percent increase over losses of $(2.09) per share from the same period last year. The company reported quarterly sales of $3.08 million which missed the analyst consensus estimate of $3.32 million by 7.12 percent. This is a 77.52 percent increase over sales of $1.74 million the same period last year.

Earnings Misses

Evoke Pharma Q1 EPS $(0.51) Misses $(0.33) Estimate, Sales $3.08M Miss $3.32M Estimate

<h3>Gainers</h3>
<ul>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares rose 15.1% to $3.66 during Tuesday's after-market session. The company's market cap stands at $19.5 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares increased by 11.11% to $4.9. The market value of their outstanding shares is at $68.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares moved upwards by 10.89% to $20.25. The market value of their outstanding shares is at $356.7 million. The company's, Q1 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) stock moved upwards by 10.0% to $0.33. The company's market cap stands at $14.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 9.84% to $0.42. The company's market cap stands at $11.8 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 9.35% to $0.49. The market value of their outstanding shares is at $71.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 20.7% to $37.0 during Tuesday's after-market session. The company's market cap stands at $3.6 billion. The company's, Q1 earnings came out today. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 18.44% to $5.93. The company's market cap stands at $546.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 16.87% to $0.78. The market value of their outstanding shares is at $3.0 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock fell 8.82% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 8.49% to $1.51. The market value of their outstanding shares is at $2.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 8.48% to $1.08. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDSX

CPIX

HBIO

LPCN

MYGN

ONMD

RIGL

SRPT

THAR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly sales of $3.31 million which beat the analyst consensus estimate of $3.08 million by 7.26 percent. This is a 97.37 percent increase over sales of $1.68 million the same period last year.

Earnings Beats

Evoke Pharma Q4 Sales $3.31M Beat $3.08M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $11.76 million. 
• Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $28.55 million. 
• Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $15.80 million. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is expected to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $54.11 million. 
• Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) is expected to report earnings for its fourth quarter. 
• US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $4.54 million. 
• Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $37.36 million. 
• G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $807.11 million. 
• Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report earnings for its fourth quarter. 
• Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is projected to report quarterly loss at $0.16 per share on revenue of $13.39 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $8.67 million. 
• D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $2.23 million. 
• Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $81.68 million. 
• Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $204.70 million. 
• CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $27.99 million. 
• Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $50.53 million. 
• Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $10.26 billion. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $147.53 million. 
• Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is estimated to report earnings for its fourth quarter. 
• Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $499.61 million. 
• Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is projected to report quarterly loss at $0.49 per share on revenue of $142.21 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $25.15 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report earnings for its fourth quarter. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is expected to report earnings for its fourth quarter. 
• Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $76.67 million. 
• Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is likely to report quarterly loss at $0.47 per share on revenue of $2.67 million. 
• Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter. 
• Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is estimated to report earnings for its fourth quarter. 
• Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly loss at $0.07 per share on revenue of $47.75 million. 
• Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $252.86 million. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $451.76 million. 
• Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $42.80 million. 
<h3>Companies Reporting After The Bell</h3>
• Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $394.49 million. 
• DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $761.31 million. 
• Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.08 per share on revenue of $130.60 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is likely to report quarterly earnings at $1.82 per share on revenue of $1.63 billion. 
• Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is expected to report earnings for its third quarter. 
• Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is likely to report quarterly loss at $0.35 per share on revenue of $118.90 million. 
• Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.10 per share on revenue of $10.37 million. 
• Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) is projected to report quarterly loss at $0.21 per share on revenue of $9.09 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is expected to report earnings for its fourth quarter. 
• Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is estimated to report quarterly earnings at $0.77 per share on revenue of $253.99 million. 
• Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is expected to report earnings for its fourth quarter. 
• Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.63 per share on revenue of $3.08 million. 
• Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $161.36 million. 
• FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is expected to report quarterly loss at $0.04 per share on revenue of $29.02 million. 
• aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) is projected to report earnings for its fourth quarter. 
• Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $142.61 million. 
• PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $7.70 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $108.91 million. 
• Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is expected to report quarterly loss at $0.18 per share on revenue of $12 thousand. 
• Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $2.77 million. 
• WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $46.00 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $250.17 million. 
• Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $276.46 million. 
• OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $92.09 million. 
• Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $30.77 million. 
• HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is estimated to report earnings for its fourth quarter. 
• Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $102.27 million. 
• AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is expected to report earnings for its fourth quarter. 
• PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is likely to report quarterly loss at $0.11 per share on revenue of $14.30 million. 
• Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is projected to report quarterly loss at $1.11 per share on revenue of $23.52 million. 
• Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $22.29 million. 
• Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $81.42 million. 
• ZOMEDICA CORP COM (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $8.10 million. 
• GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is projected to report quarterly loss at $0.11 per share on revenue of $42.21 million. 
• Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $40.13 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $119.53 million. 
• EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $170.48 million. 
• Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $36.08 million. 
• AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $74.60 million. 
• Origin Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $9.08 million. 
• Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $12.30 million. 
• Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is likely to report quarterly loss at $0.39 per share on revenue of $232.91 million. 
• Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $348.33 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its first quarter. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is estimated to report quarterly earnings at $7.13 per share on revenue of $3.47 billion. 
• Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.33 million. 
• Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $5.00 million. 
• Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $28.95 million. 
• BuzzFeed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZFD#NASDAQ">BZFD</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACTG

AFCG

AGRO

AKBA

ALLO

ALTI

APYX

ASPS

ATYR

AUID

AVAH

BAER

BEAT

BLDE

BLDP

BLNK

BZFD

CCLD

CION

CLLS

CLRB

CNTY

DLTH

DOCU

EVCM

FEIM

FUTU

GIII

GRWG

GURU

HGBL

JYNT

LCUT

LRFC

MAPS

MCRB

NOTE

NYXH

OPAL

ORGN

PANL

PESI

PHAR

PLBY

PRPL

PSQH

PTMN

QBTS

QNRX

RBRK

RGNX

SHIM

SKLZ

SMTC

SOHO

TACT

TBCH

TTAN

ULTA

USEG

VERI

VUZI

XNET

XPOF

ZSPC

ZUMZ

Earnings Scheduled For March 13, 2025

Evoke Pharma shares are trading higher after the company highlighted GIMOTI as a solution for Gastroparesis treatment after the Domperidone supply comes to an end.

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE;&nbsp;(metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA's recent update regarding domperidone supply. As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI&#xAE; (metoclopramide) is uniquely positioned to address the ongoing needs of patients facing challenges with alternative therapies.

Biotech

General

Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025

Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE;&nbsp;(metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company's robust intellectual property estate for its innovative GIMOTI&#xAE; (metoclopramide) nasal spray.
The two patent applications, U.S. 17/366,839 and U.S. 17/366,818, entitled "Nasal Formulations of Metoclopramide," provide Evoke with additional claims protecting the intranasal administration of metoclopramide for the treatment of gastroparesis. When issued, these patents will bolster the Company's position as the provider of the only FDA-approved, non-oral, patient administered therapy for acute and recurrent diabetic gastroparesis in the US. The two patents are expected to be Orange Book listable and expire at the end of 2029.
One of the key challenges in treating gastroparesis is ensuring effective drug absorption, as delayed stomach emptying often compromises the efficacy of orally administered medications. GIMOTI bypasses the GI tract, offering patients a reliable and effective treatment option.

Evoke Pharma Receives Notices Of Allowance For 2 Additional U.S. Patent Applications Protecting GIMOTI

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.38) by 147.37 percent. The company reported quarterly sales of $2.70 million which missed the analyst consensus estimate of $3.36 million by 19.59 percent. This is a 72.74 percent increase over sales of $1.56 million the same period last year.

Evoke Pharma Q3 2024 GAAP EPS $(0.94) Misses $(0.38) Estimate, Sales $2.70M Miss $3.36M Estimate

Shares of V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected<a href="https://www.benzinga.com/news/earnings/24/10/41587808/vf-corp-q2-earnings-revenue-beat-eps-beat-cost-reductions-on-track-guidance-and-more"> second-quarter financial results.</a>
VF Corp, the parent company of Vans and The North Face, reported second-quarter revenue of $2.8 billion, beating the consensus estimate of $2.7 billion, according to Benzinga Pro. The company reported second-quarter earnings of 60 cents per share, beating analyst estimates of 37 cents per share.
V.F. Corporation shares jumped 21.4% to $20.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) gained 68.2% to $2.22 in pre-market trading after the company announced it finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine.</li>
<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) rose 67.6% to $2.23 in pre-market trading after falling 18% on Monday.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares surged 30% to $3.51 in pre-market trading.</li>
<li>Immuron Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares rose 29% to $2.49 in pre-market trading.</li>
<li>Lightbridge Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) climbed 15.4% to $10.48 in pre-market trading after jumping around 24% on Monday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 14.8% to $1.47 in pre-market trading. Quantum Computing will host a conference call and webcast on Wednesday, Nov. 6, to review the Company&#8217;s operational progress for the third quarter.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) gained 11.1% to $242.50 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and approved an additional $1 billion buyback program.</li>
<li>Veea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) shares gained 10.7% to $4.32 in pre-market trading. Veea, O.N.E. Amazon, and AECOM partnered on &#8216;Internet of Forests&#8217; to digitally safeguard rainforests and empower Colombian communities.</li>
<li>Griid Infrastructure Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRDI#NASDAQ">GRDI</a>) shares rose 9.4% to $1.01 in pre-market trading after dipping 16% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hanryu Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRYU#NASDAQ">HRYU</a>) shares dipped 40.4% to $0.3031 in pre-market trading after jumping 125% on Monday.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares fell 25.8% to $93.69 in pre-market trading following downbeat quarterly results.</li>
<li>CVR Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) shares fell 25.8% to $17.68 in pre-market trading after the company reported weak quarterly results and said it will not pay cash dividend for the third quarter.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 21.3% to $0.1217 in today's pre-market trading after the company announced the pricing of $3 million public offering of common stock and/or pre-funded warrants.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) fell 16.6% to $0.26 in pre-market trading after jumping 40% on Monday.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) fell 16% to $5.95 in pre-market trading. Evoke Pharma shares jumped 38% on Monday after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) shares declined 15.8% to $12.48 in pre-market trading after reporting third-quarter results.</li>
<li>Iveda Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) declined 15.6% to $1.40 in pre-market trading.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 11% to $26.27 after the company reported mixed third-quarter financial results.</li>
<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) fell 10.1% to $26.20 in pre-market trading after gaining 14% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41592226/dow-surges-over-250-points-ahead-of-alphabet-pfizer-earnings-investor-sentiment-improves-fear-index">Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

AMKR

AREB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DBGI

FFIV

GRDI

HLIT

HRYU

IMRN

IVDA

LIXT

LTBR

QUBT

SHPH

TMDX

VEEA

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 51.6% to $2.0 during Monday's after-market session. The company's market cap stands at $5.8 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares increased by 12.99% to $2.26. The company's market cap stands at $25.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares moved upwards by 12.01% to $4.01. The company's market cap stands at $33.2 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 7.5% to $1.0. The company's market cap stands at $16.2 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock moved upwards by 6.61% to $1.45. The market value of their outstanding shares is at $40.5 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock increased by 5.92% to $0.44. The company's market cap stands at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares fell 28.6% to $90.2 during Monday's after-market session. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares fell 21.62% to $0.24. The market value of their outstanding shares is at $7.4 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 18.06% to $14.61. The market value of their outstanding shares is at $51.4 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 8.62% to $6.47. The market value of their outstanding shares is at $4.7 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares fell 6.2% to $0.79. The market value of their outstanding shares is at $16.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock declined by 5.84% to $2.58. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNPX

MNPR

NXTC

ONCO

SYRA

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Monday.
The Dow traded up 0.77% to 42,440.12 while the NASDAQ rose 0.46% to 18,603.67. The S&amp;P 500 also rose, gaining, 0.43% to 5,832.99.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Financials shares rose by 1.2% on Monday.
In trading on Monday, energy shares fell by 0.7%.
Top Headline
Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) reported third-quarter adjusted EPS of 0.32 euros (or $0.35), missing the consensus of 0.35 euros. The Dutch conglomerate reported sales of 4.38 billion euros ($4.74 billion), down 2% year over year and missing the consensus of 4.54 billion euros.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares shot up 106% to $1.19 &nbsp;after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies.</li>
<li>Shares of Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) got a boost, surging 70% to $13.08 &nbsp;after the company reported preliminary results from its clinical trial of RF Ablation technology where 100% of its responder group was able to eliminate opioid use and reduce pain scores.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 52% to $7.78 after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares dropped 16% to $26.52 after the company reported third-quarter EPS and sales below estimates and revised its 2024 outlook due to weak demand in China.</li>
<li>Shares of Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) were down 7% to $4.38. The stock may be moving on continued weakness following Friday&#8217;s reported preliminary third-quarter financial results.</li>
<li>CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) was down, falling 9% to $5.46 following weak quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 6% to $67.49 while gold traded down 0.1% at $2,754.40.
Silver traded up 0.2% to $33.850 on Monday, while copper fell 0.1% to $4.3655.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.41%, Germany's DAX rose 0.35% and France's CAC 40 rose 0.79%. Spain's IBEX 35 Index rose 0.77%, while London's FTSE 100 rose 0.45%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.82%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite Index gaining 0.68% and India's BSE Sensex surging 0.76%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
The Federal Reserve Bank of Dallas&#8217; general business activity index for manufacturing in Texas rose to -3 in October compared to a reading of -9 in the earlier month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

AMIX

BORR

HCTI

S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 124.5% to $1.3 during Monday's regular session. The market value of their outstanding shares is at $7.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares increased by 117.99% to $10.66. The market value of their outstanding shares is at $654.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 69.81% to $9.0. The company's market cap stands at $6.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 44.51% to $6.72. The company's market cap stands at $87.4 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares moved upwards by 36.31% to $12.95. The market value of their outstanding shares is at $693.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 30.8% to $2.59. The company's market cap stands at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 18.3% to $4.91 during Monday's regular session. The company's market cap stands at $25.5 million. </li>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 15.92% to $26.63. The market value of their outstanding shares is at $24.8 billion. The company's, Q3 earnings came out today. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 14.11% to $2.62. The company's market cap stands at $447.0 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 13.83% to $1.62. The market value of their outstanding shares is at $36.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 12.85% to $0.73. The company's market cap stands at $1.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 12.73% to $1.44. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

GLUE

ITRM

SONN

TVGN

12 Health Care Stocks Moving In Monday's Intraday Session

Health Care

Press Releases

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Comments

Evoke Pharma

Intérêt court

Evoke Pharma (NASDAQ:EVOK) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL